Latest news for Design Milk (OTC:AHAHF) Stock

Design Milk Co Ltd is a leader in the modern design, digital media, ecommerce, and interior and architectural trade and consumer industries.

DESIGN MILK CO LTD NEW by DESIGN MILK CO LTD.

Design Milk Co Ltd

Intuitive Surgical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NYSE">ISRG</a>) short percent of float has risen 10.42% since its last report. The company recently reported that it has 3.74 million shares sold short, which is 1.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.48 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Intuitive Surgical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726060521_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Intuitive Surgical has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Intuitive Surgical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Intuitive Surgical's peer group average for short interest as a percentage of float is 2.85%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

ISRG

How Is The Market Feeling About Intuitive Surgical?

Texas Instruments's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NYSE">TXN</a>) short percent of float has risen 3.24% since its last report. The company recently reported that it has 20.32 million shares sold short, which is 2.23% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Texas Instruments Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726060516_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Texas Instruments has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Texas Instruments's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Texas Instruments's peer group average for short interest as a percentage of float is 5.51%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Texas Instruments?

Magnolia Oil &amp; Gas's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGY#NYSE">MGY</a>) short percent of float has fallen 3.98% since its last report. The company recently reported that it has 30.22 million shares sold short, which is 19.06% of all regular shares that are available for trading. Based on its trading volume, it would take traders 12.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Magnolia Oil &amp; Gas Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726060511_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Magnolia Oil &amp; Gas has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Magnolia Oil &amp; Gas's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Magnolia Oil &amp; Gas's peer group average for short interest as a percentage of float is 4.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Magnolia Oil & Gas?

Wedbush analyst Jay McCanless maintains Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) with a Neutral and raises the price target from $15 to $18.

News

Price Target

Analyst Ratings

Wedbush Maintains Neutral on Rocket Companies, Raises Price Target to $18

Bumble Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) remains invested in artificial intelligence-powered features to compete with <a href="https://www.benzinga.com/topic/online-dating">online dating rivals like Tinder.</a>
CEO Lidiane Jones showcased upcoming AI tools during Goldman Sachs&#8217; annual technology conference, with plans to leverage AI to improve photo selection, conversation prompts, and profile creation for its users, TechCrunch <a href="https://techcrunch.com/2024/09/10/bumble-to-leverage-ai-to-help-users-with-profiles-and-conversations/" target="_blank" rel="noreferrer noopener">reports</a>. Tinder has 9.6 million paying users, whereas Bumble has 2.8 million as of the second quarter of 2024. 
Bumble looks to launch the AI innovations by winter and aims to reduce the anxiety users face during profile creation.
These updates follow Bumble&#8217;s ongoing focus on integrating AI into its services to remove fake profiles and blur inappropriate images.
The company is also focusing on improving its free experience.
Bumble reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40232453/bumble-inc-announces-second-quarter-2024-results" rel="noreferrer noopener">second-quarter topline</a> growth of 3.4% to $268.6 million, missing the analyst consensus of $271.8 million. Total paying users reached 4.1&nbsp;million, from 3.6 million a year ago. Bumble App revenue increased 4.8% to $218.0 million. Bumble expects third-quarter revenue of $269 million-$275 million versus the $273 million estimate. <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40251709/these-analysts-slash-their-forecasts-on-bumble-after-q2-results" rel="noreferrer noopener">Multiple analysts downgraded</a> the stock&#8217;s rating and cut their price targets as the quarterly print disappointed the Street.
Analyst Chandler Willison acknowledged a <a href="https://www.benzinga.com/markets/equities/24/08/40247012/bumble-shares-are-down-almost-40-in-premarket-and-gen-z-millennials-are-to-blame-for-their-chang">slowdown in growth</a> for Bumble, similar to Tinder, including a market saturation.
Bumble stock plunged over 59% in the last 12 months.
Price Action: BMBL stock is up 1.56% at $6.50 premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40812228/exclusive-is-apple-falling-behind-rivals-like-amazon-alphabet-wisdomtrees-christopher-ga">EXCLUSIVE: Is Apple &#8216;Falling Behind&#8217; Rivals Like Amazon, Alphabet? WisdomTree&#8217;s Christopher Gannatti Weighs In</a></li>
</ul>
Photo: Shutterstock

Media

BMBL

Bumble Bets On AI Tools To Revive Growth In Online Dating Market

At the European Association for the Study of Diabetes annual meeting, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shared an abstract with data from the company&#8217;s next-generation <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37562828/novo-nordisk-sets-timeframe-for-its-next-gen-experimental-obesity-drug" rel="noreferrer noopener">weight loss candidate, amycretin</a>.
Earlier today, Novo Nordisk&nbsp;announced that its weight-loss drug liraglutide is safe and effective for children <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40809053/novo-nordisk-reports-positive-results-of-weight-loss-drug-liraglutide-for-children-as-young-as-6" rel="noreferrer noopener">as young as six</a>.
The company-funded study revealed a 7.4% reduction in body mass index for children aged 6 to 12 who used the injectable pens over a year compared to a placebo group.
Amycretin is a novel protein-based unimolecular amylin (regulates hunger) and GLP-1 receptor co-agonist for once-daily oral administration.
GLP-1 (produced in the small intestine to regulate blood sugar) is the same hormone targeted by other weight loss drugs like Novo Nordisk&#8217;s Wegovy (semaglutide) and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound (tirzepatide).
In a single-center, placebo-controlled, double-blinded <a target="_blank" href="https://www.easd.org/media-centre/home.html#!resources/b-safety-tolerability-and-weight-reduction-findings-of-oral-amycretin-a-novel-amylin-and-glucagon-like-peptide-1-receptor-co-agonist-in-a-first-in-human-study-b-70062cca-bdca-47a3-a603-124d45236f6f" rel="noreferrer noopener">study</a>, adult participants with a BMI of 25.0-39.9 kg/m2 without diabetes were randomized to receive amycretin or a placebo once a day for up to 12 weeks.
In the first-in-human trial, a 50-mg dose of the daily pill of amycretin, led to 10.4% weight loss at about three months after the start of treatment.
Participants who took two 50-mg pills daily lost 13.1% of their weight compared to 1.1% in the placebo group for both doses.
According to Novo Nordisk, the drug is safe, with side effects in line with those of Ozempic and Wegovy.
Most adverse events reported were mild to moderate in severity and related to gastrointestinal discomfort (e.g., nausea, vomiting), and decreased appetite.
In a similar&nbsp;trial, participants who were taking Wegovy showed a weight loss of&nbsp;<a target="_blank" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796491" rel="noreferrer noopener">5.9%</a> after 12 weeks.
Wegovy&nbsp;<a target="_blank" href="https://www.wegovy.com/about-wegovy/why-wegovy.html" rel="noreferrer noopener">showed</a> an overall weight loss of 15% after two years of treatment vs. 2.6% (~6 lb) for adults taking a placebo.
At the end of the treatment period, participants taking amycretin did not reach a plateau in weight loss, indicating the potential for further weight loss with extended use.
The study&#8217;s authors conclude that daily oral amycretin treatment in adults who are overweight or obese and without diabetes demonstrated a safe and tolerable profile in line with the drug receptor classes and with notable reductions in body weight.
&#8220;A single molecule that targets both amylin and GLP-1 biology in a tablet form could offer a more convenient approach to achieving better outcomes for individuals with overweight or obesity,&#8221; researchers <a target="_blank" href="https://www.yahoo.com/news/ozempic-maker-touts-remarkable-more-220100220.html" rel="noreferrer noopener">said</a> before presenting the findings.
Price Action: NVO stock is up 2.53% at $133.06 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40802152/neurology-focused-harmony-biosciences-gains-confidence-with-wakix-sales-surge-strat" target="_blank" rel="noreferrer noopener">Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says</a>.</li>
</ul>
Ozempic injection Image By Natalia Varlei On Shutterstock

Biotech

Large Cap

Health Care

Movers

General

Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy

B of A Securities analyst Chi Fong maintains Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) with a Neutral and raises the price target from $12 to $12.5.

ROIV

B of A Securities Maintains Neutral on Roivant Sciences, Raises Price Target to $12.5

WIIM

Quhuo shares are trading higher. The company announced that Cloud Alliance has dissolved its 25.96% stake in the company

Telsey Advisory Group analyst Dana Telsey maintains Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) with a Market Perform and maintains $10 price target.

Telsey Advisory Group Maintains Market Perform on Designer Brands, Maintains $10 Price Target

The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read sequencing to enhance the diagnosis and treatment of subfertility and recurrent miscarriages (RPL). &nbsp;
The HiFi Solves Sub-fertility Consortium integrates DNAstack's federated data platform, the world's first solution to enable the creation and analysis of global federated networks of data in compliance with industry standards set by the Global Alliance for Genomics &amp; Health. This platform allows for seamless global collaboration on complex datasets without the need to move the data, ensuring sensitive genomic information remains secure while supporting efficient analysis and compliance with regional data governance.
Under the leadership of Associate Professor Saumya S. Jamuar, the consortium brings together esteemed experts: Professor Vorasuk Shotelersuk from the Center of Excellence for Medical Genomics, Chulalongkorn University, Thailand; Professor Ming Chen from Changhua Christian Hospital Medical Center, Taiwan; Assistant Professor Jee Soo Lee from Seoul National University College of Medicine (SNUCM) Laboratory Medicine, South Korea; and Associate Professor Sohyun Hwang, CHA Bundang Medical Center, CHA University School of Medicine, South Korea. Together, they are breaking new ground in fertility research with the goal of revolutionizing care for millions affected by subfertility and RPL globally.

Global

PACB

PacBio HiFi Long-Read Sequencing Consortium, Led By KK Women's And Children's Hospital In Singapore, Is Pioneering The Use Of PacBio's Technology To Enhance The Diagnosis And Treatment Of Subfertility And Recurrent Miscarriages

MPLN

MultiPlan shares are trading lower after the company announced a 1-for-40 reverse stock split.

Latest innovations include Oracle Database@AWS, Oracle Database@Azure, Oracle Database@Google Cloud, OCI Dedicated Region, OCI Supercluster, and OCI Roving Edge Infrastructure&nbsp;
Oracle Cloud is available in more locations than any other hyperscaler, with many more regions planned
LAS VEGAS, Sept. 11, 2024 /PRNewswire/ -- Oracle CloudWorld -- Oracle today announced new <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4251906-14&amp;h=2665755716&amp;u=https%3A%2F%2Fwww.oracle.com%2Fcloud&amp;a=Oracle+Cloud+Infrastructure">Oracle Cloud Infrastructure</a>&nbsp;(OCI) <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4251906-14&amp;h=861308427&amp;u=https%3A%2F%2Fwww.oracle.com%2Fcloud%2Fdistributed-cloud%2F&amp;a=distributed+cloud">distributed cloud</a>&nbsp;innovations to help meet the rapidly growing global demand for its AI and cloud services. The latest innovations span Oracle Database@AWS, Oracle Database@Azure, Oracle Database@Google Cloud, OCI Dedicated Region, and OCI Supercluster. With Oracle's distributed cloud, customers can deploy OCI's 150+ AI and cloud services at the edge, in their own datacenter, across clouds, or in the public cloud and can help address a variety of data privacy, sovereign AI, and low latency requirements. In addition, Oracle Cloud is available in more locations than any other hyperscaler, with 85 regions live and 77 planned.

ORCL

Oracle Expands Its Distributed Cloud Capabilities To Help Organizations Innovate With AI

DA Davidson analyst Linda Bolton Weiser maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Buy and maintains $223 price target.

DA Davidson Maintains Buy on e.l.f. Beauty, Maintains $223 Price Target

Mission-Driven Differentiated Media Company Will Continue to Be Led by Co-Founder, Neal Harmon &nbsp;
Attractive Angel Guild Community Has Membership Based Recurring Revenue Model
Angel Studios Revenues of $45.0 Million for the Six Months Ended June 30, 2024, Up from $39.0 Million for the Six Months Ended 2023
Transaction With No Minimum Cash Condition, Closing Expected to be Completed in the First Half of 2025, Seeks to Support Company's Continued Bitcoin Treasury Strategy
PROVO, Utah and DEL MAR, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Angel Studios—the studio empowering everyday fans to greenlight development and distribution of movies and TV shows—today announced it has entered into a definitive agreement to become a publicly listed company through a business combination with Southport Acquisition Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PORT#OTC">PORT</a>) ("Southport"), a special purpose acquisition company. Upon the closing of the transaction, the combined company's Class A common stock is expected to be listed on the NYSE or Nasdaq under the ticker symbol "AGSD".

IPOs

PORT

Angel Studios To Become A Publicly Traded Company Via Business Combination With Southport Acquisition Corp; The Combined Company's Class A Common Stock Is Expected To Be Listed On The NYSE Or Nasdaq Under The Ticker Symbol "AGSD"

Editor&#8217;s note: This story has been updated with additional details. 
The U.S. annual inflation rate in August fell to its lowest point since February 2021, signaling a further easing of pressure on the cost of goods and <a href="https://www.benzinga.com/topic/inflation">services for U.S. consumers.</a>
The Consumer Price Index (CPI) saw a cooler-than-anticipated annual headline print in August, cementing convictions for interest rate cuts&nbsp;by the Federal Reserve.
<h3 class="wp-block-heading">August CPI Inflation Report: Key Highlights</h3>
<ul>
<li>Headline CPI inflation fell from 2.9% in July to 2.5% in August 2024 on a year-over-year basis, falling short of the consensus forecast of 2.6% tracked by TradingEconomics.</li>
<li>On a monthly basis, inflation increased by 0.2% in August, matching both the previous month&#8217;s reading and expectations.</li>
<li>The energy index declined by 0.8% in the month, following a stagnation in the previous month.</li>
<li>The shelter index soared by 0.5% in August, contributing the most to the overall increase in the all-items index.</li>
<li>Core inflation, which excludes volatile energy and food items, held steady at 3.2% year-over-year in August, matching forecasts.</li>
<li>On a monthly basis, core inflation rose by 0.3%, accelerating from the previous 0.2% and surpassing estimates of 0.2%.</li>
<li>In August, several items saw increases, including shelter, airline fares, motor vehicle insurance, education and apparel.</li>
<li>The items for used cars and trucks, household furnishings and operations, medical care, communication and recreation were among those that recorded a decline over the month.</li>
</ul>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Consumer Price Index</th>
<th>August 2024</th>
<th>July 2024</th>
<th>Expected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headline (y/y)</td>
<td>2.5%</td>
<td>2.9%</td>
<td>2.6%</td>
</tr>
<tr>
<td>Headline (m/m)</td>
<td>0.2%</td>
<td>0.2%</td>
<td>0.2%</td>
</tr>
<tr>
<td>Core (y/y)</td>
<td>3.2%</td>
<td>3.2%</td>
<td>3.2%</td>
</tr>
<tr>
<td>Core (m/m)</td>
<td>0.3%</td>
<td>0.2%</td>
<td>0.2%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Market Reactions</h3>
Investors focused on the unexpected rise in core monthly inflation than the drop in the annual headline figure, sending Treasury yields and the U.S. dollar higher after the report.
The U.S. dollar, as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), climbed 0.3% minutes after the release, while yields on the 10-year Treasury note surged by 8 basis points.
Rate-sensitive assets like gold and the Japanese yen fell, and futures on major U.S. equity indices saw minor declines.
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.3% in Wednesday's premarket trading. Tech stocks, as tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) traded 0.1% lower. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40810739/wall-street-poised-for-pullback-ahead-of-august-cpi-data-strategist-says-further-dip-likely-before-">Wall Street Poised For Pullback Ahead Of August CPI Data: Strategist Says Further Dip Likely Before Rally Resumes Following Next Week&#8217;s Fed Meeting</a></li>
</ul>
Photo via Shutterstock.

Macro Economic Events

Econ #s

Economics

Markets

PowerShares DB US Dollar Index Bullish Fund

Inflation Slows To 2.5% In August, Lowest Rate Since February 2021: Core Index Remains Sticky (UPDATED)

Tuesday,&nbsp;Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) Rybrevant&nbsp;(amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40804959/dexamethasone-reduces-infusion-related-reactions-in-patients-with-egfr-mutated-non-small-cell-lung" rel="noreferrer noopener">L858R substitution mutations</a>.
Data were presented at the&nbsp;International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC).
The 40-patient study showed that prophylaxis with 8-mg dexamethasone taken for two days before the first infusion met the primary endpoint of incidence of IRRs at Cycle 1 Day 1 (C1D1), with an all-grades IRR rate for IV Rybrevant&nbsp;of 22.5%.
This represents a three-fold reduction in the incidence of IRRs compared to standard management of IRRs with IV Rybrevant, where historical data has observed an all-grades incidence rate of 67.4%.
All IRRs were mild or moderate (Grade 1 or 2), with no patients requiring hospitalization due to IRRs. No Grade 3 or higher IRR events were reported.
Over the last weekend, Johnson &amp; Johnson&nbsp;presented longer follow-up data from the landmark Phase 3 MARIPOSA study which showed first-line treatment with Rybrevant combined with Lazcluze (lazertinib) provided consistent benefit across long-term outcomes compared to osimertinib monotherapy in adult NSCLC patients with EGFR exon 19 deletions or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n40764394/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-show-strong-favorable-overall-survival-trend-v" rel="noreferrer noopener">L858R substitution mutations</a>.
The data show a strong and improving overall survival (OS) trend favoring Rybrevant plus Lazcluze at approximately three years of follow-up.
<ul>
<li>61% of patients receiving Rybrevant plus Lazcluze&nbsp;were alive compared to 53% of those treated with osimertinib (Median OS not estimable vs 37.3 months).</li>
</ul>
Overall survival will continue to be assessed with longer term follow-up as a key secondary endpoint.
Results further showed Rybrevant plus Lazcluze demonstrated a trend toward improved central nervous system disease control compared to osimertinib at three years.
<ul>
<li>Intracranial PFS was double for Rybrevant plus Lazcluzeversus osimertinib (38% vs. 18%, respectively).</li>
</ul>
More patients remained on treatment with the Rybrevant plus Lazcluze combination compared to osimertinib (40% vs. 29%).
Additionally, more patients receiving Rybrevant plus Lazcluze at the three-year follow-up had not started a subsequent therapy versus osimertinib (45% vs. 32%).
Progression-free survival after the first subsequent therapy was 57% for Rybrevant plus Lazcluze combination compared to 49% for osimertinib.
In&nbsp;August 2024, the FDA approved Rybrevant plus Lazcluze following a Priority Review as a first-line therapy for patients with&nbsp;EGFR-mutated NSCLC based on the favorable efficacy and safety profile demonstrated in this study.
Price Action: JNJ stock is up 0.09% at $167.53 during the premarket session at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40812280/at-t-ceo-john-stankey-flags-normalizing-wireless-trends-and-strong-fiber-growth-details" target="_blank" rel="noreferrer noopener">AT&amp;T CEO John Stankey Flags Normalizing Wireless Trends And Strong Fiber Growth: Details</a>.</li>
</ul>
Photo: Shutterstock

Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions

Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) with a Outperform and maintains $5 price target.

Reiteration

NUVB

Wedbush Reiterates Outperform on Nuvation Bio, Maintains $5 Price Target

U.S. sovereign designed DCG modems enable warfighters and military assets to easily roam across commercial and purpose-built networks
Sept. 11, 2024--Comtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) ("the Company"), a global technology leader, today announced the launch of the Company's new Digital Common Ground ("DCG") portfolio of modems. Comtech's DCG product line is designed to enable the U.S. Department of Defense ("DoD") and coalition partners to move to digitized, hybrid satellite network architectures, which will bring forward a new era of secure, resilient, interoperable, and ubiquitous connectivity across all domains.

CMTL

Comtech Launches New Digital Common Ground Modem Product Line For DoD And Coalition Customers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Ascendiant Capital raised the price target for Atossa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) from $6.25 to $6.5. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Atossa Therapeutics shares gained 7.4% to close at $1.46 on Tuesday. <a href="https://www.benzinga.com/quote/atos/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut the price target for Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from $135 to $130. B of A Securities analyst Graham Perry downgraded the stock from Buy to Neutral. Novartis shares fell 0.2% to close at $116.99 on Tuesday. <a href="https://www.benzinga.com/quote/NVS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Camden National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NYSE">CAC</a>) price target from $40 to $41. Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintained a Market Perform rating. Camden National shares fell 0.3% to close at $37.78 on Tuesday. <a href="https://www.benzinga.com/quote/CAC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Supernus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPN#NASDAQ">SUPN</a>) price target from $41 to $36. Piper Sandler analyst David Amsellem downgraded the stock from Overweight to Neutral. Supernus Pharmaceuticals shares fell 1.2% to close at $33.49 on Tuesday. <a href="https://www.benzinga.com/quote/SUPN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from $100 to $120. B of A Securities analyst Omar Dessouky maintained a Buy rating. AppLovin shares fell 0.1% to close at $86.23 on Tuesday. <a href="https://www.benzinga.com/quote/APP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel boosted Krystal Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) price target from $204 to $220. Stifel analyst Dae Gon Ha maintained a Buy rating. Krystal Biotech shares fell 1.4% to close at $185.00 on Tuesday. <a href="https://www.benzinga.com/quote/KRYS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut Dave &amp; Buster&#8217;s Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) price target from $65 to $55. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Dave &amp; Buster&#8217;s shares fell 0.8% to close at $29.86 on Tuesday. <a href="https://www.benzinga.com/quote/PLAY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) from $11 to $10. Wedbush analyst Michael Pachter maintained an Underperform rating. GameStop shares fell 3.3% to close at $23.45 on Tuesday. <a href="https://www.benzinga.com/quote/GME/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) price target from $60 to $63. Truist Securities analyst Joseph Civello maintained a Buy rating. Academy Sports shares gained 5.2% to close at $55.38 on Tuesday. <a href="https://www.benzinga.com/quote/ASO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $525 to $510. BMO Capital analyst Andrew Strelzik maintained an Outperform rating. Domino&#8217;s shares fell 0.8% to close at $416.77 on Tuesday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DPZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-1024x534.png" alt="" class="wp-image-542314" style="width:481px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/11090617/image-87.png 1276w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Pre-Market Outlook

ATOS

KRYS

PLAY

SUPN

Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday

FEMY

Femasys shares are trading higher after the company announced distribution partnerships for the commercialization of FemaSeed for over $1.3 million in the Spanish market.

Design Milk Co. Ltd. (AU:DMC) has released an update. Design Milk Co. Limited reported a net increase in cash and cash equivalents with $161,000 fo...

Design Milk Co. Sees Positive Cash Flow

Design Milk Co. Ltd. (AU:DMC) has released an update. Design Milk Co. Limited has announced the immediate appointment of Mr. David Willington as a ...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Design Milk

News

Latest news for Design Milk (OTC:AHAHF) Stock